DK2016089T3 - Gendefekter og mutant-alk-kinase i humane faste tumorer - Google Patents

Gendefekter og mutant-alk-kinase i humane faste tumorer

Info

Publication number
DK2016089T3
DK2016089T3 DK07775495.0T DK07775495T DK2016089T3 DK 2016089 T3 DK2016089 T3 DK 2016089T3 DK 07775495 T DK07775495 T DK 07775495T DK 2016089 T3 DK2016089 T3 DK 2016089T3
Authority
DK
Denmark
Prior art keywords
alk
mutant
kinase
gene defects
human fixed
Prior art date
Application number
DK07775495.0T
Other languages
English (en)
Inventor
Klarisa Rikova
Herbert Haack
Laura Sullivan
Ting-Lei Gu
Ailan Guo
Joan Macneil
Jian Yu
Anthony Possemato
Original Assignee
Cell Signaling Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Signaling Technology Inc filed Critical Cell Signaling Technology Inc
Application granted granted Critical
Publication of DK2016089T3 publication Critical patent/DK2016089T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
DK07775495.0T 2006-04-14 2007-04-13 Gendefekter og mutant-alk-kinase i humane faste tumorer DK2016089T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79236406P 2006-04-14 2006-04-14
PCT/US2007/009273 WO2008127248A1 (en) 2007-04-13 2007-04-13 Gene defects and mutant alk kinase in human solid tumors

Publications (1)

Publication Number Publication Date
DK2016089T3 true DK2016089T3 (da) 2014-04-22

Family

ID=39864195

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07775495.0T DK2016089T3 (da) 2006-04-14 2007-04-13 Gendefekter og mutant-alk-kinase i humane faste tumorer

Country Status (9)

Country Link
EP (1) EP2016089B1 (da)
JP (1) JP5562640B2 (da)
KR (3) KR101274092B1 (da)
CN (2) CN101466721B (da)
AU (1) AU2007351581B2 (da)
CA (2) CA2648864C (da)
DK (1) DK2016089T3 (da)
ES (1) ES2458497T3 (da)
WO (1) WO2008127248A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) * 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
PT2450437T (pt) 2006-04-14 2017-08-25 Cell Signaling Technology Inc Defeitos de genes e cinase alk mutante em tumores sólidos humanos
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二(芳胺基)芳基化合物
EP2255190A4 (en) * 2008-02-12 2011-05-04 Brigham & Womens Hospital FISH TEST FOR EML4-ALK FUSION IN LUNG CANCER
AU2010248782B2 (en) * 2009-05-15 2015-06-11 Insight Genetics, Inc. Methods and compositions relating to fusions of ALK for diagnosing and treating cancer
TWI518325B (zh) 2010-02-04 2016-01-21 自治醫科大學 對alk抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
WO2011102507A1 (ja) * 2010-02-22 2011-08-25 富士レビオ株式会社 癌遺伝子の同定方法、癌遺伝子発現細胞の樹立方法、および癌遺伝子標的薬のスクリーニング方法
CN101955995B (zh) * 2010-06-17 2013-06-26 江苏迈迪基因生物科技有限公司 淋巴瘤相关的融合基因的诊断试剂盒
KR101264810B1 (ko) * 2010-11-25 2013-05-15 한국과학기술연구원 Alk 유전자의 재배열 검출방법 및 이를 이용한 암 진단방법
CA2823337C (en) 2010-12-29 2019-09-10 Expression Pathology, Inc. Her3 protein srm/mrm assay
CN102719525B (zh) * 2012-04-12 2014-06-04 厦门艾德生物医药科技有限公司 用于检测eml4-alk融合基因突变的引物、探针及检测试剂盒
US9084456B1 (en) * 2012-05-28 2015-07-21 Jack Zemer Linkage for jewelry components
EP3470513B1 (en) * 2013-03-15 2020-05-13 Expression Pathology, Inc. Srm assay to indicate cancer therapy
US10072298B2 (en) 2013-04-17 2018-09-11 Life Technologies Corporation Gene fusions and gene variants associated with cancer
AU2014254394B2 (en) * 2013-04-17 2020-06-18 Life Technologies Corporation Gene fusions and gene variants associated with cancer
EP3122901B1 (en) * 2014-03-27 2018-08-15 Life Technologies Corporation Gene fusions and gene variants associated with cancer
JP6533128B2 (ja) * 2014-09-01 2019-06-19 アークレイ株式会社 Alk融合遺伝子を増幅するためのプライマー試薬、それを含むalk融合遺伝子の増幅試薬キット、それを用いたalk融合遺伝子の増幅方法および分析方法
EP2990493B1 (en) * 2014-09-01 2017-05-24 ARKRAY, Inc. Primer reagent for amplifying alk fusion gene, alk fusion gene amplification reagent kit including the same, and alk fusion gene amplification method and alk fusion gene analysis method using the same
WO2016106701A1 (zh) * 2014-12-31 2016-07-07 深圳华大基因股份有限公司 检测非小细胞肺癌的qRT-PCR引物、探针、芯片、试剂盒、应用和方法
CN105254764A (zh) * 2015-08-27 2016-01-20 上海康岱生物医药技术有限公司 ACVR1-Fc融合蛋白及其制法和用途
WO2017153932A1 (en) 2016-03-10 2017-09-14 Novartis Ag Strn-alk fusion as a therapeutic target in gastric cancer
WO2017175111A1 (en) 2016-04-04 2017-10-12 Novartis Ag Strn-alk fusion as a therapeutic target in colorectal cancer
EP3631011B1 (en) * 2017-05-31 2021-06-23 Roche Diagnostics GmbH Multiplex pcr detection of alk, ret, and ros fusions
KR101987065B1 (ko) 2017-08-07 2019-06-10 주식회사 싸이토젠 Eml4-alk유전자 변이 분석방법
KR102182850B1 (ko) * 2018-11-19 2020-11-25 경북대학교 산학협력단 Tfg 나노 입자 또는 tfmg 나노 입자를 포함하는 암 치료용 또는 암 전이 억제용 조성물
JP7385191B2 (ja) * 2019-08-30 2023-11-22 学校法人同志社 Eml4-alk阻害ペプチドおよびこれを含む肺がん治療薬
CN112794914B (zh) * 2019-11-14 2022-09-16 深圳华大生命科学研究院 一种基于噬菌体展示技术开发的alk纳米抗体及其应用
JP2020156481A (ja) * 2020-04-06 2020-10-01 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト固形腫瘍における遺伝子欠失及び突然変異alkキナーゼ
CN113130001B (zh) * 2021-03-31 2023-07-18 甘肃中医药大学 一种天然化合物与抗肿瘤化合物配伍的筛选方法
AU2023304031A1 (en) 2022-07-04 2025-02-06 Chugai Seiyaku Kabushiki Kaisha Combination drug
TW202425998A (zh) 2022-08-30 2024-07-01 日商中外製藥股份有限公司 併用醫藥

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529925A (en) * 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US7300753B2 (en) * 1998-09-04 2007-11-27 John Rush Immunoaffinity isolation of modified peptides from complex mixtures
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
US20030229910A1 (en) * 2002-04-17 2003-12-11 Richard Metz Short fragment homologous replacement to provide BSE resistant cattle
US20070105839A1 (en) * 2003-09-18 2007-05-10 Patricia Imbach 2, 4-Di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
CA2543257C (en) * 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
EP1914240B1 (en) * 2006-10-11 2009-12-02 Astellas Pharma Inc. EML4-ALK fusion gene
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene

Also Published As

Publication number Publication date
CN101466721B (zh) 2013-08-21
EP2016089B1 (en) 2014-01-15
WO2008127248A1 (en) 2008-10-23
KR20110117734A (ko) 2011-10-27
CN101466721A (zh) 2009-06-24
CA2648864C (en) 2017-11-21
ES2458497T3 (es) 2014-05-05
KR101274092B1 (ko) 2013-06-25
EP2016089A1 (en) 2009-01-21
CA2982018C (en) 2023-10-17
CA2982018A1 (en) 2008-10-23
AU2007351581A1 (en) 2008-10-23
KR20100005180A (ko) 2010-01-14
HK1122040A1 (en) 2009-05-08
CA2648864A1 (en) 2008-10-23
JP5562640B2 (ja) 2014-07-30
EP2016089A4 (en) 2009-10-21
KR101362284B1 (ko) 2014-02-12
KR20130004522A (ko) 2013-01-10
JP2010501175A (ja) 2010-01-21
CN112057625A (zh) 2020-12-11
AU2007351581B2 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
DK2016089T3 (da) Gendefekter og mutant-alk-kinase i humane faste tumorer
DK1844074T3 (da) Humane antistoffer og proteiner
DK2287195T3 (da) Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi
DK3067064T3 (da) Modificerede rsv-f-proteiner og fremgangsmåder til anvendelse deraf
KR101413615B9 (ko) 인간 프로토피브릴에 선택적인 개선된 항체 및 이의 용도
IL191759A (en) Ganaxolone formulations and methods for the making and use thereof
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK1951885T3 (da) Fructooligosaccharidfremstilling in situ og saccharosereduktion
PL2450437T3 (pl) Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych
DK1984344T3 (da) Multicykliske aminosyrederivater og fremgangsmåder til anvendelse heraf
DK2268317T3 (da) Integrin-targeteringssubstanser og in vivo- og in vitro-billeddannelsesmetoder som anvender samme
SI1971366T1 (sl) Humana protitelesa anti-il-23, sestavki, postopki in uporabe
DK2252633T3 (da) Anti-TrkA antistoffer og derivater deraf
DE602006009191D1 (de) Bildaufnahmegerät und -verfahren
DK3028564T4 (da) Dyremodeller og terapeutiske molekyler
DK2081955T3 (da) Metastinderivater og anvendelse deraf
EP1895838A4 (en) COMPOSITIONS AND METHODS
DK2190991T3 (da) SDF-1-Bindende nucleinsyrer og anvendelsen deraf
DK3401327T3 (da) Genprodukter med forskellig ekspression i tumorer og anvendelser deraf
EP2012798A4 (en) USE OF INOSITOL-TRIPYROPHOSPHATE IN THE TREATMENT OF TUMORS AND DISEASES
EP2089420A4 (en) PROTEINS FOR USE IN THE DIAGNOSIS AND TREATMENT OF INFECTIONS AND DISEASES
DK2131682T3 (da) Autoklave og fremgangsmåde
DK2293846T3 (da) Depsipeptider og deres terapeutiske anvendelse
FI20050327A0 (fi) Antennijärjestelmä ja menetelmä antennin yhteydessä sekä antenni
DK1885716T3 (da) Thiazolderivater og anvendelse deraf